diabetic retinopathy

View All

Pharma News for Gilead, Incannex, Avidity
Eylea HD Injection 8 Mg Approved By FDA; Veopoz Receives FDA Approval for CHAPLE Disease Treatment; FDA Places Second Partial Clinical Hold on AML Enrollment for Magrolimab Trials; FDA Approval to Incannex’s Sleep Apnoea Clinical Trial; FDA Orphan Drug Designation to Avidity’s AOC 1044; Orphan Drug Designation to CanariaBio’s MAb-AR20.5

Eylea HD Injection 8 Mg Approved By FDA for Treatment of Wet AMD, DME, and Diabetic Retinopathy The FDA has approved Regeneron Pharmaceuticals’ EYLEA HD (aflibercept) Injection of 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retin...

Find More

Diabetic Retinopathy
Diabetic Retinopathy: The Hornet’s Nest of Diabetes Mellitus

Diabetic Retinopathy (DR), a microvascular disease, is an eye condition in diabetic patients, affecting blood vessels in the retina and causing significant visual loss in working populations. The retina needs a constant supply of blood, which it receives through a network of tiny blood vessels. Constant high blood ...

Find More

eye-disorders-treatment-market-Errors-Refractive-Age-Related-Macular-Degeneration-Cataract-Glaucoma-Diabetic-Retinopathy-Novartis-Roche-Eyenovia-Allergan
How Pharmaceutical Companies Are Mitigating The Gap In The Eye Disorders Treatment Market

The eyes are one of the most precious and delicate parts of the human body. Around 80% of the information from the surrounding environment that the human perceives comes from our eyes. The eyes require the best protection and care, as a slight disability can severely impact day-to-day activities and can also have l...

Find More

Johnson & Johnson
Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M

Atreca secured USD 125 Million when solid tumor trial comes into picture California based company, Atreca has bagged USD 125 million to establish its R&D activities. As the company gears up, the series C round enters, to move its lead solid tumor drug into the clinic.  Atreca has set up its credentials through V...

Find More